Taking stock of the drug industry, from the lab to the medicine chestFebruary 15, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer RONNY HARTMANN/AFP via Getty Images STAT+ | In about-face, Moderna vows Americans won't have to pay for its Covid-19 vaccine The reversal came as Sen. Bernie Sanders scheduled a hearing next month about Moderna's initial decision to charge Americans for its shot. By Ed Silverman and Sarah Owermohle STAT+ | Biogen, having 'lost its way,' looks to drug launches for Alzheimer's and depression for return to growth "We have two major products to launch ... that's not an opportunity you have very often," said Biogen CEO Chris Viehbacher. By Adam Feuerstein STAT+ | Biden administration pitches 3 big new drug pricing reform experiments The Biden administration is pitching three new experiments aimed at bringing down drug prices for Medicare and Medicaid patients. By Rachel Cohrs and John Wilkerson Drew Angerer/Getty Images FDA advisers recommend approval of over-the-counter naloxone to fight opioid overdose Approval would make available a nasal spray form of the drug, known as Narcan, to use against opioid overdoses. By Lev Facher Opinion: Beyond Medicare and Social Security: Cutting Medicaid after the pandemic would be political madness Proposals to cut Medicaid should be off the table because of the essential care it allows more than 90 million Americans to access. By Arielle Kane More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments